STERIS (NYSE:STE) Shares Sold Off Rep. April McClain Delaney

Representative April McClain Delaney (Democratic-Maryland) recently sold shares of STERIS plc (NYSE:STE). In a filing disclosed on August 03rd, the Representative disclosed that they had sold between $1,001 and $15,000 in STERIS stock on July 24th.

Representative April McClain Delaney also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Life Time Group (NYSE:LTH) on 7/31/2026.
• Purchased $15,001 – $50,000 in shares of Liberty Media Corporation – Liberty Formula One Series C (NASDAQ:FWONK) on 7/31/2026.
• Sold $1,001 – $15,000 in shares of Corpay (NYSE:CPAY) on 7/31/2026.
• Purchased $15,001 – $50,000 in shares of C.H. Robinson Worldwide (NASDAQ:CHRW) on 7/31/2026.
• Sold $1,001 – $15,000 in shares of STERIS (NYSE:STE) on 7/31/2026.
• Purchased $15,001 – $50,000 in shares of Somnigroup International (NYSE:SGI) on 7/30/2026.
• Purchased $1,001 – $15,000 in shares of Entegris (NASDAQ:ENTG) on 7/30/2026.
• Sold $1,001 – $15,000 in shares of Corpay (NYSE:CPAY) on 7/30/2026.
• Purchased $1,001 – $15,000 in shares of Life Time Group (NYSE:LTH) on 7/30/2026.
• Sold $1,001 – $15,000 in shares of Service Corporation International (NYSE:SCI) on 7/30/2026.

STERIS Price Performance

Shares of NYSE STE opened at $233.15 on Thursday. STERIS plc has a twelve month low of $195.14 and a twelve month high of $269.44. The stock’s 50 day moving average price is $214.04 and its 200-day moving average price is $225.66. The company has a market capitalization of $22.72 billion, a PE ratio of 29.40 and a beta of 0.91. The company has a quick ratio of 1.54, a current ratio of 2.09 and a debt-to-equity ratio of 0.25.

STERIS (NYSE:STE) last issued its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.49 by $0.10. The company had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.49 billion. STERIS had a return on equity of 14.15% and a net margin of 13.18%.STERIS’s revenue was up 7.3% on a year-over-year basis. During the same period last year, the business posted $2.34 earnings per share. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. On average, equities analysts anticipate that STERIS plc will post 11.17 EPS for the current year.

STERIS Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Stockholders of record on Friday, September 4th will be paid a $0.69 dividend. This represents a $2.76 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Friday, September 4th. This is a boost from STERIS’s previous quarterly dividend of $0.63. STERIS’s dividend payout ratio (DPR) is presently 31.78%.

Insider Activity

In other STERIS news, VP John Adam Zangerle sold 1,419 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $209.28, for a total transaction of $296,968.32. Following the sale, the vice president owned 35,259 shares of the company’s stock, valued at $7,379,003.52. The trade was a 3.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard C. Breeden sold 1,481 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $209.51, for a total value of $310,284.31. Following the sale, the director owned 38,964 shares in the company, valued at approximately $8,163,347.64. This represents a 3.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 7,328 shares of company stock valued at $1,554,051 over the last quarter. Company insiders own 1.12% of the company’s stock.

Institutional Trading of STERIS

Hedge funds have recently made changes to their positions in the company. Generali Investments Management Co LLC bought a new position in shares of STERIS during the 2nd quarter worth $262,000. Fulton Bank N.A. lifted its holdings in STERIS by 10.4% during the second quarter. Fulton Bank N.A. now owns 2,881 shares of the medical equipment provider’s stock valued at $607,000 after purchasing an additional 272 shares during the last quarter. Elevation Wealth Partners LLC lifted its holdings in STERIS by 1,130.0% during the second quarter. Elevation Wealth Partners LLC now owns 123 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 113 shares during the last quarter. Czech National Bank boosted its position in STERIS by 4.5% during the second quarter. Czech National Bank now owns 27,916 shares of the medical equipment provider’s stock worth $5,878,000 after purchasing an additional 1,206 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in shares of STERIS by 56.5% in the second quarter. Assenagon Asset Management S.A. now owns 76,440 shares of the medical equipment provider’s stock worth $16,096,000 after purchasing an additional 27,594 shares in the last quarter. 94.69% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

STE has been the subject of several research analyst reports. Weiss Ratings lowered STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 27th. UBS Group initiated coverage on shares of STERIS in a report on Tuesday, July 28th. They issued a “buy” rating and a $275.00 price target on the stock. Piper Sandler restated an “overweight” rating and set a $270.00 price target on shares of STERIS in a research report on Thursday, May 21st. Wall Street Zen lowered shares of STERIS from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, KeyCorp dropped their target price on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $277.25.

STERIS News Roundup

Here are the key news stories impacting STERIS this week:

• Positive Sentiment: Earnings exceeded expectations: STERIS reported adjusted earnings of $2.59 per share, above the $2.49–$2.54 analyst consensus and up from $2.34 a year earlier. Revenue rose 7.3% year over year to approximately $1.5 billion. Steris Q1 Earnings Surpass Estimates
• Positive Sentiment: Broad-based operating growth: Healthcare revenue increased 8% to $1.05 billion, Applied Sterilization Technologies revenue rose 6% to $297.6 million, and Life Sciences revenue grew 9% to $146.7 million. Constant-currency organic revenue growth was 6%.
• Positive Sentiment: Growth investment supports longer-term prospects: STERIS plans to invest $600 million in a North Carolina formulated-chemistries manufacturing and distribution center to support sterilization and disinfection demand from healthcare and pharmaceutical customers. Steris to Invest in North Carolina Manufacturing Hub
• Neutral Sentiment: Fiscal 2027 outlook was maintained: The company reiterated revenue growth guidance of 7% to 8% and adjusted EPS guidance of $11.10 to $11.30, broadly in line with analyst expectations. Capital expenditures are expected to increase to approximately $450 million, while free-cash-flow guidance is about $800 million.
• Negative Sentiment: Near-term costs and cash-flow pressures: The North Carolina project and related restructuring are expected to generate approximately $55 million to $70 million in pretax charges over time. Operating cash flow declined to $367.1 million from $420.0 million in the prior-year quarter, while higher capital spending could weigh on near-term free cash flow.
• Negative Sentiment: Insider selling may temper sentiment: Company insiders reported five open-market sales and no purchases over the past six months, although these transactions are not necessarily tied to the quarterly results.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.